The Avicenna Alliance is dedicated to ensuring the full innovation cycle of predictive medicine is represented.
The Virtual Physiological Human (VPH) Initiative, carries a non-diminishable 50% board representation on the Avicenna Alliance with Industry representatives from Medical Devices, Pharmaceuticals and Software also maintaining a 50% board membership.
The VPH Institute is a massive network of Research Organisations and Universities engaged in predictive or in silico medicine.
The VPH institute has its origins in a European Commission endorsed research area on computer modelling and simulation and has been active for over 10 years.
This partnership of industry and academia allows the Avicenna Alliance to address challenges to the predictive or in silico market from pre-clinical research all the way to post-market.
NEWS
News
Avicenna Alliance Submits MDR Revision Proposals to the European Commission
The Avicenna Alliance is pleased to announce that, in a letter sent to the European Commissioner for Health and Animal Welfare, Olivér Várhelyi, we have formally submitted our proposals for the revision of the Medical Devices Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) to the European Commission.
Advancing In Silico Medicine: Strengthening Dialogue with EU Policymakers
On February 17, our President & Secretary General Thierry Marchal, alongside Nayara Maldonado Solís from RPP, had the opportunity to meet with the team of MEP Kulja, MD, to discuss the creation of an MEP In Silico Coalition. This initiative would establish a regular dialogue between in silico experts from the Avicenna Alliance and the VPH Institute, and MEPs committed to new technologies in healthcare.
